Pharmaceutical - Par Pharmaceutical

Filter

Current filters:

Par Pharmaceutical

Popular Filters

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor

19-07-2012

US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

NovaDel regains rights for ondansetron oral spray product

22-01-2012

New Jersey, USA-based NovaDel Pharma (OTCBB: NVDL) has announced the termination of certain license agreements…

BioAlliance PharmaLicensingNovaDel PharmaOncologyondansetronPar PharmaceuticalPharmaceuticalTalon Therapeutics

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top